February 14, 2019
In
Business Events, News Archive, Patently Obvious®
Catalyst Pharmaceutical’s Firdapse price hike – Patently Obvious®
Senator Bernie Sanders wrote an open letter to Catalyst Pharmaceuticals on the 4th of February regarding their newly FDA approved drug to treat Lambert-Eaton Myasthenic Syndrome, saying “Catalyst’s decision to set the annual list price at $375,000 is not only a blatant fleecing of American taxpayers, but is also an immoral exploitation of patients who need this medication.”
Seeing this, M·CAM decided to investigate. What follows is a report on a company that has leveraged the patent system and orphan drug act against their intended use to profit on the suffering of vulnerable patients.
Download the Patently Obvious® report here
Sorry, the comment form is closed at this time.